Mardi, 11 Août 2020
Dernières nouvelles
Principale » Top Performer of the day: Horizon Pharma plc (HZNP)

Top Performer of the day: Horizon Pharma plc (HZNP)

09 Août 2017

Horizon Pharma PLC (NASDAQ:HZNP) received a $18.00 price target from stock analysts at Piper Jaffray Companies in a research note issued to investors on Monday. Vanguard Group Inc. now owns 12,749,275 shares of the biopharmaceutical company's stock worth $188,434,000 after buying an additional 506,596 shares in the last quarter.

Horizon Pharma PLC announced that its Board of Directors has authorized a stock repurchase program on Monday, May 8th that allows the company to buyback 1,000% of outstanding shares. Jefferies Group LLC set a $26.00 target price on Horizon Pharma PLC and gave the company a "buy" rating in a research report on Wednesday, April 12th. BMO Capital Markets reissued a "buy" rating and issued a $17.00 target price (down from $24.00) on shares of Horizon Pharma PLC in a research report on Tuesday, May 9th. Zweig invested 0.02% in Horizon Pharma PLC (NASDAQ:HZNP). The stock presently has an average rating of "Buy" and an average target price of $19.57. SELL rating has been given by 0 analyst (s) and 8 analyst (s) given BUY rating to the stock.

Horizon Pharma plc (HZNP) added 4.72% to reach $13.3 in the previous trading session.

Horizon Pharma plc (HZNP) has an Analysts' Mean Recommendation of 1.8, according to data compiled by Finviz. The firm's market capitalization is $2.20 billion.

Livforsakringsbolaget Skandia Omsesidigt Maintains Position in Incyte Corporation (INCY)
Raymond James Financial, Inc. reiterated a "hold" rating on shares of Incyte Corporation in a research note on Monday, April 17th. Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics.

Horizon Pharma PLC (HZNP) traded up 4.72% during midday trading on Monday, hitting $13.30.

Ireland based company, Horizon Pharma Public Limited Company (HZNP)'s latest closing price distance was at -15.84% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at 8.16% and 0.00% compared with the 20 Day Moving Average. Company fiscal year is ending in September and analysts' consensus recommendation is Outperform for COL and estimated EPS for next quarter is $ 1.58. Horizon Pharma PLC had a positive return on equity of 21.74% and a negative net margin of 42.40%. The original version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/07/amalgamated-bank-has-292000-stake-in-horizon-pharma-plc-hznp-updated-updated.html. Earnings, adjusted for non-recurring costs, were 41 cents per share. On average, equities research analysts forecast that Horizon Pharma PLC will post $0.99 earnings per share for the current year. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & worldwide trademark & copyright law. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of United States & worldwide copyright & trademark laws. Horizon Pharma PLC (NASDAQ:HZNP) has declined 28.13% since August 7, 2016 and is downtrending. This buyback authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's board of directors believes its stock is undervalued. 10,000 Horizon Pharma PLC (NASDAQ:HZNP) shares with value of $94,800 were bought by GREY MICHAEL G. It dropped, as 40 investors sold HZNP shares while 69 reduced holdings. Profund Advisors LLC boosted its stake in shares of Horizon Pharma PLC by 0.8% in the first quarter. Hodges Capital Management Inc. now owns 2,409,396 shares of the biopharmaceutical company's stock worth $35,611,000 after buying an additional 230,905 shares during the last quarter. Sheaff Brock Investment Advisors LLC purchased a new position in Horizon Pharma PLC during the first quarter valued at about $148,000. First Dallas Securities Inc. boosted its stake in Horizon Pharma PLC by 9.4% in the first quarter. Shares saw a steep increase in trading volume of 117.73% over the normal average daily volume. As of the end of the quarter Cim Investment Mangement Inc had sold a total of 519 shares trimming its position 3.0%. Pyrrho Mgmt LP has invested 2.28% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP). The company's previous year sales total was 257380.

At the same time, Horizon Pharma completed its acquisition of River Vision and its biologic, teprotumumab.